TY - JOUR
T1 - Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept
T2 - 2-Year outcomes
AU - Bathon, J.
AU - Robles, M.
AU - Ximenes, A. C.
AU - Nayiager, S.
AU - Wollenhaupt, J.
AU - Durez, P.
AU - Gomez-Reino, J.
AU - Grassi, W.
AU - Haraoui, B.
AU - Shergy, W.
AU - Park, S. H.
AU - Genant, H.
AU - Peterfy, C.
AU - Becker, J. C.
AU - Covucci, A.
AU - Moniz Reed, D.
AU - Helfrick, R.
AU - Westhovens, R.
PY - 2011/11
Y1 - 2011/11
N2 - Objective: To assess the efficacy and safety of abatacept plus methotrexate versus methotrexate alone in early erosive rheumatoid arthritis (RA). Methods: The AGREE was a 2-year phase IIIb multinational study in early (≤2 years) RA. During the double-blind period (year 1), patients were randomly assigned 1:1 to receive abatacept+methotrexate or methotrexate alone; all patients received open-label abatacept + methotrexate during year 2. Clinical outcomes assessed included 28-joint disease activity score (DAS28) defined remission, low disease activity score (LDAS), American College of Rheumatology (ACR) responses and physical function. Radiographic outcomes were assessed using the Genant-modified Sharp total score (TS). Safety was monitored throughout. Results: Of the 459 patients completing year 1, 433 patients (94.3%) completed year 2. DAS28-defined remission, LDAS, ACR and physical function were sustained through year 2 in the original abatacept+methotrexate group, with 55.2% in remission at 2 years. Upon introduction of abatacept in the methotrexate-alone group, additional patients achieved DAS28-defined remission (44.5% vs 26.9%), LDAS (60.4% vs 43.2%) and improved ACR 70 (49.8% vs 31.7%) for year 2 versus year 1. Less radiographic progression was observed at 2 years in the original abatacept+methotrexate group than the methotrexatealone group (change in TS 0.84 vs 1.75, p
AB - Objective: To assess the efficacy and safety of abatacept plus methotrexate versus methotrexate alone in early erosive rheumatoid arthritis (RA). Methods: The AGREE was a 2-year phase IIIb multinational study in early (≤2 years) RA. During the double-blind period (year 1), patients were randomly assigned 1:1 to receive abatacept+methotrexate or methotrexate alone; all patients received open-label abatacept + methotrexate during year 2. Clinical outcomes assessed included 28-joint disease activity score (DAS28) defined remission, low disease activity score (LDAS), American College of Rheumatology (ACR) responses and physical function. Radiographic outcomes were assessed using the Genant-modified Sharp total score (TS). Safety was monitored throughout. Results: Of the 459 patients completing year 1, 433 patients (94.3%) completed year 2. DAS28-defined remission, LDAS, ACR and physical function were sustained through year 2 in the original abatacept+methotrexate group, with 55.2% in remission at 2 years. Upon introduction of abatacept in the methotrexate-alone group, additional patients achieved DAS28-defined remission (44.5% vs 26.9%), LDAS (60.4% vs 43.2%) and improved ACR 70 (49.8% vs 31.7%) for year 2 versus year 1. Less radiographic progression was observed at 2 years in the original abatacept+methotrexate group than the methotrexatealone group (change in TS 0.84 vs 1.75, p
UR - http://www.scopus.com/inward/record.url?scp=80053571014&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053571014&partnerID=8YFLogxK
U2 - 10.1136/ard.2010.145268
DO - 10.1136/ard.2010.145268
M3 - Article
C2 - 21821865
AN - SCOPUS:80053571014
SN - 0003-4967
VL - 70
SP - 1949
EP - 1956
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 11
ER -